Japan approvals include Kymriah as Japan's first CAR T therapy

Japanese regulators approved a basket of drugs on Tuesday, including the first CAR T cell therapy in Japan.

Novartis AG (NYSE:NVS; SIX:NOVN) said Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Kymriah tisagenlecleucel to treat CD19-positive relapsed or refractory B cell acute lymphoblastic leukemia (ALL) and CD19-positive relapsed or refractory diffuse large B cell lymphoma (DLBCL)...